Vaxart Valuation
| VXRT Stock | USD 0.68 0.04 5.58% |
Vaxart is undervalued. Vaxart Inc has a current Real Value of $1.7 per share. The regular price of the company is $0.67979997. Our model measures the value of Vaxart Inc from inspecting the company fundamentals such as Current Valuation of 124.21 M, shares owned by insiders of 0.87 %, and Return On Equity of -0.92 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Vaxart's valuation include:
Price Book 2.4067 | Enterprise Value | Enterprise Value Ebitda (0.17) | Price Sales 11.6778 | Forward PE 42.735 |
Undervalued
Today
Please note that Vaxart's price fluctuation is dangerous at this time. Calculation of the real value of Vaxart Inc is based on 3 months time horizon. Increasing Vaxart's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Vaxart's intrinsic value may or may not be the same as its current market price of 0.68, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.68 | Real 1.7 | Target 4.83 | Hype 0.68 | Naive 0.64 |
The intrinsic value of Vaxart's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Vaxart's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Vaxart Inc helps investors to forecast how Vaxart stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Vaxart more accurately as focusing exclusively on Vaxart's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Vaxart's intrinsic value based on its ongoing forecasts of Vaxart's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Vaxart's closest peers.
Vaxart Cash |
|
Vaxart Valuation Trend
Vaxart's real value is important for investors to make better decisions and a more accurate overall view of Vaxart's financial worth over time. Using both Vaxart's enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Vaxart Total Value Analysis
Vaxart Inc is at this time projected to have valuation of 124.21 M with market capitalization of 162.65 M, debt of 26.51 M, and cash on hands of 129.55 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Vaxart fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
124.21 M | 162.65 M | 26.51 M | 129.55 M |
Vaxart Investor Information
About 18.0% of the company outstanding shares are owned by institutional investors. The book value of Vaxart was at this time reported as 0.38. The company recorded a loss per share of 0.4. Vaxart Inc last dividend was issued on the 9th of November 2012. The entity had 1:11 split on the 14th of February 2018. Based on the key indicators related to Vaxart's liquidity, profitability, solvency, and operating efficiency, Vaxart Inc is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Vaxart Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Vaxart has an asset utilization ratio of 8.04 percent. This implies that the Company is making $0.0804 for each dollar of assets. An increasing asset utilization means that Vaxart Inc is more efficient with each dollar of assets it utilizes for everyday operations.Vaxart Ownership Allocation
Vaxart Inc shows a total of 227.48 Million outstanding shares. About 81.33 % of Vaxart outstanding shares are held by general public with 0.87 (%) owned by insiders and only 17.8 % by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Vaxart Profitability Analysis
The company reported the previous year's revenue of 7.38 M. Net Loss for the year was (82.47 M) with loss before overhead, payroll, taxes, and interest of (52.27 M).About Vaxart Valuation
The stock valuation mechanism determines Vaxart's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Vaxart Inc based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Vaxart. We calculate exposure to Vaxart's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Vaxart's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -54.7 M | -52 M | |
| Pretax Profit Margin | (12.81) | (13.45) | |
| Operating Profit Margin | (12.99) | (13.64) | |
| Net Loss | (12.85) | (13.49) | |
| Gross Profit Margin | (9.47) | (9.00) |
Vaxart Growth Indicators
Investing in growth stocks can be very risky. If the company such as Vaxart does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 144.8 M | |
| Forward Price Earnings | 42.735 |
Vaxart Current Valuation Indicators
Vaxart's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Vaxart's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Vaxart, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Vaxart's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Vaxart's worth.Additional Tools for Vaxart Stock Analysis
When running Vaxart's price analysis, check to measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.